Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the publication of a paper in the Journal of Clinical Gastroenterology. The paper reports data using GeneNews' proprietary Sentinel Principle(R) platform technology to identify complex changes in blood gene expression patterns that were differentially regulated between active and inactive Crohn's disease.

22 Oct 2009

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Curis, Inc. , a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 8th Annual BIO Investor Forum at 4:30 p.m. PDT (7:30 p.m. EDT) on October 28, 2009, at the Palace Hotel in San Francisco, California.

21 Oct 2009

Exact Sciences to use Hologic's Invader chemistry for colorectal cancer screening

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has obtained a worldwide license from Hologic Inc. for that company’s Invader, Invader plus and real-time Invader detection chemistries for the field of colorectal cancer screening.

From Hologic, Inc. 21 Oct 2009

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

19 Oct 2009

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

Chrysanthemum indicum extract holds promise for treating human cancer

A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects. Recently, much attention has been devoted to the anticancer activity of Chrysanthemum indicum, especially in hepatocellular carcinoma (HCC). However, its anticancer mechanism of action is still not clear and needs further investigation.

19 Oct 2009

Immune-related proteins are potential drug targets for gastric inflammation and cancer

A research team from South Korea studied the complex reaction of gastric inflammation induced by Helicobacter pylori (H pylori) in a systematic manner using a protein interaction network. Their study will be published on September 28, 2009 in the World Journal of Gastroenterology.

19 Oct 2009

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Small-for-size graft dysfunction (SFSGD) following living-related liver transplantation (LRLT) is characterized by early graft dysfunction (EGD) when the graft-to-recipient body weight ratio (GRBWR) is below 0.8%.

19 Oct 2009

Early detection of PGAP may reduce mortality rate

Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate.

19 Oct 2009

ADI and CeTeCancer collaborate for research project

Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer -- a Chilean-based research laboratory -- to validate the effectiveness of Radient Pharmaceuticals' Onko-Sure™ in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

15 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

Virginia Health Information releases HMO quality and satisfaction reports

Virginia Health Information (VHI), a nonprofit health information company, reports HMO quality and satisfaction reports at www.vhi.org.

13 Oct 2009

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

The National Committee for Quality Assurance (NCQA), with support from The California Endowment, has recognized five managed care plans for their innovative efforts to improve health care access and quality for consumers facing language and cultural barriers that frequently impede their access to life-prolonging care.

13 Oct 2009

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.

13 Oct 2009

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Orion Genomics today announced that it has entered into a multi-year collaboration and license agreement with the molecular diagnostics unit of Novartis Pharma AG. Under the collaboration, the parties seek to discover novel epigenetic biomarkers, and both parties have rights to independently develop and commercialize diagnostic products in their respective fields.

12 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

GeneNews announces the publication of a paper in the Journal of Clinical Gastroenterology

Research suggests latent cytomegalovirus infection exacerbates inflammatory bowel disease

Curis to outline Hedgehog Pathway Inhibitor at Annual BIO Investor Forum

Exact Sciences to use Hologic's Invader chemistry for colorectal cancer screening

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Research study on EGFR and HER2 expressions in BTC

Chrysanthemum indicum extract holds promise for treating human cancer

Immune-related proteins are potential drug targets for gastric inflammation and cancer

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Early detection of PGAP may reduce mortality rate

ADI and CeTeCancer collaborate for research project

Older generation antibiotic for treating colon cancer

Virginia Health Information releases HMO quality and satisfaction reports

Health plans efforts to improve health care access to patients facing language barrier recognized by NCQA

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Orion Genomics enters collaboration and license agreement with Novartis Pharma

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Industry Focus eBook: Oncology eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Industry Focus eBook: Oncology eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in